Low Molecular Weight Heparins (LMWH) are an application of pharmacological anticoagulant intervention which are derived from UFH by chemical
Low Molecular Weight Heparins (LMWH) are an application of pharmacological anticoagulant intervention which are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third how big heparin. Low molecular weight heparin is employed for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectral range of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are However, it's associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, when compared with unfractionated heparin (UFH), for thromboembolic indications.
Low Molecular Weight Heparins comes from an unfractionated heparin with an average molecular weight of significantly less than 8,000 Da. Low molecular weight heparins are extracted by enzymatic or chemical depolymerization of unfractionated heparin. Low molecular weight heparins have fewer side effects when compared with unfractionated heparins, which involve lesser risk of heparin-induced osteopenia and heparin-induced thrombocytopenia (HIT). Currently, low molecular weight heparin forms the typical of care drugs and is widely employed for the therapy and prophylaxis of arterial and venous thrombosis. Dose consideration for low molecular weight heparin is dependent upon a patient's weight.
Low Molecular Weight Heparins (LMWH) is really a class of anticoagulant medications. They are used in the prevention of blood clots and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in treating myocardial infarction.
See Full Report@ https://bit.ly/3yIKpK2

Comments
Post a Comment